Compare ATCH & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | HOWL |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | United States | United States |
| Employees | 43 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 29.7M |
| IPO Year | N/A | 2021 |
| Metric | ATCH | HOWL |
|---|---|---|
| Price | $0.24 | $0.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 6.9M | 423.0K |
| Earning Date | 02-13-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $14,613,715.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.72 | ★ N/A |
| Revenue Growth | ★ 52.99 | N/A |
| 52 Week Low | $0.14 | $0.53 |
| 52 Week High | $13.19 | $2.38 |
| Indicator | ATCH | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 47.35 |
| Support Level | $0.23 | $0.59 |
| Resistance Level | $0.28 | $0.74 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 28.52 | 29.72 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.